Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 6/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | APAF1 | O14727 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9828182 | 0.92 | KMT2A (0.79) | KMT2APOLBMAPTKDM4EALDH1A1 | |
| SCHEMBL9828399 | 0.92 | KMT2A (0.66) | KMT2APOLBMAPTKDM4EALDH1A1 | |
| SCHEMBL9828492 | 0.91 | KMT2A (0.64) | KMT2APOLBMAPTKDM4EALDH1A1 | |
| SCHEMBL9827887 | 0.90 | KMT2A (0.63) | KMT2APOLBMAPTKDM4EALDH1A1 | |
| SCHEMBL9827437 | 0.89 | POLB (0.62) | KMT2APOLBMAPTKDM4EALDH1A1 | |
| SCHEMBL7368133 | 0.89 | KMT2A (0.64) | KMT2APOLBMAPTKDM4EALDH1A1 | |
| SCHEMBL8760332 | 0.87 | MAPT (0.57) | KMT2APOLBMAPTKDM4EALDH1A1 | |
| SCHEMBL8488336 | 0.84 | POLB (0.56) | KMT2APOLBMAPTKDM4EALDH1A1 | |
| SCHEMBL7375489 | 0.81 | KMT2A (0.55) | KMT2APOLBMAPTKDM4EALDH1A1 | |
| SCHEMBL27890025 | 0.81 | POLB (1.00) | KMT2APOLBMAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0201765-B1 | 3(2H)PYRIDAZINONE, PROCESS FOR ITS PREPARATION AND ANTI-ALLERGIC AGENT CONTAINING IT | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1991-09-18 | — | — | EP | claimed |
| US-4892947-A | 3(2H)Pyridazinone, process for its preparation and anti-allergic agent containing it | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1990-01-09 | — | — | US | claimed |
| EP-0201765-A2 | 3(2H)Pyridazinone, process for its preparation and anti-allergic agent containing it | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1986-11-20 | — | — | EP | claimed |
| US-20110104186-A1 | Small molecule immunopotentiators and assays for their detection | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2011-05-05 | — | — | US | disclosed |
| US-20110104186-A1 | Small molecule immunopotentiators and assays for their detection | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104186-A1 | Small molecule immunopotentiators and assays for their detection | ICOS, CD14, MAVS | KMT2A 3196/4885POLB 2338/4885MAPT 3391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.